EpicentRx, a clinical cancer immunotherapy company targeting both sides of the immune system to deliver cancer treatments with minimal toxicity, has raised an USD35m Series D financing using Biotech Alliances International, a Silicon Valley based life-science focused investment bank, it was reported on Friday.

This funding round will be divided into three tranches and its purpose is to progress the late-stage clinical development of EpicentRx's lead anticancer agent, RRx-001, and proprietary transgene-enhanced oncolytic adenoviral platform technology. The Series D brings the total capital raised by the company to around USD77m.

RRx-001 is a small molecule immunotherapy aimed at the CD47 – SIRP alpha axis. Presently, the drug is being assessed in combination with platinum doublet chemotherapy in the Phase three REPLATINUM trial intended for the treatment of third-line and beyond small cell lung cancer (SCLC).